Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans
キーワード
概要
説明
An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59% hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical PSP suggesting that cortical dysfunction predominates over brainstem impairments. Neuropathological examination in four patients has shown a widespread accumulation of the tau protein in the basal ganglia, the midbrain and cortical areas.
This syndrome has been associated to the regular consumption of food products derived from plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a toxic origin. We have already confirmed the neurotoxic potential of the lipophilic mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce the death of dopaminergic neurons in culture, by impairment of energy production. Chronic systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions that are damaged in patients with atypical parkinsonism. These results greatly suggest that the consumption of annonacea might contribute to the pathogenesis of the disease. The H1 subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like atypical parkinsonism in Guadeloupe.
日付
| 最終確認済み: | 10/31/2017 |
| 最初に提出された: | 11/23/2017 |
| 提出された推定登録数: | 12/04/2017 |
| 最初の投稿: | 12/10/2017 |
| 最終更新が送信されました: | 12/04/2017 |
| 最終更新日: | 12/10/2017 |
| 実際の研究開始日: | 08/02/2012 |
| 一次完了予定日: | 08/02/2018 |
| 研究完了予定日: | 08/02/2023 |
状態または病気
介入/治療
Other: Clinical and biological exam
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Other: Patients Parkinson's patient | |
| Other: witnesses: without parkinson's disease Subjects without parkinson's disease |
適格基準
| 研究の対象となる年齢 | 19 Years に 19 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - Pour les patients : 1. Patient ou tiers responsable ayant reçu une information sur l'étude et ayant signé le consentement éclairé 2. Patient âgé de plus de 18 ans 3. Patient consultant en neurologie ou en gériatrie pour symptomatologie parkinsonienne ou pour troubles cognitifs évocateurs d'une démence à corps de Lewy 4. Patient domicilié aux Antilles-Guyane Pour les témoins : 5. Conjoint ou accompagnant ayant reçu une information sur l'étude et ayant signé le consentement éclairé 6. Personne âgée de plus de 18 ans 7. Personne ne présentant pas de pathologie d'allure neurodégénérative (Parkinson, démence notamment) 8. Personne domiciliée aux Antilles-Guyane Exclusion Criteria: Pour les patients : 1. Syndrome parkinsonien secondaire (post-traumatique, vasculaire, iatrogène, post encéphalitique) 2. Patient non affilié au régime de sécurité sociale 3. En cas de difficulté de suivi le patient sera exclu de l'étude longitudinale Pour les témoins : 1. Personnes présentant des troubles cognitifs ou un syndrome parkinsonien diagnostiqué. 2. Patient non affilié au régime de sécurité sociale - |
結果
主な結果の測定
1. to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana [At the end of the Period of inclusion, around 5-6 years]
二次的な結果の測定
1. to compare the proportion of atypical forms within parkinsonian syndromes; [At the end of the Period of inclusion, around 5-6 years]
2. to characterize the entity "Parkinson-dementia complex" described in Guadeloupe ; to characterize the entity "Parkinson-dementia complex" described in Guadeloupe ; [Through study completion, an average of 11 years]
3. to determine the natural history of typical and atypical forms of parkinsonism by following a cohort of the incident cases only; [Through study completion, an average of 11 years]
4. to determine the implication of a toxic alimentary factor in the etiopathogenesis of atypical forms and compare the results in the 3 areas (Guadeloupe, Guyane, Martinique); [Through study completion, an average of 11 years]
5. to determine the latency of cognitive decline in idiopathic Parkinson's disease in the 3 areas ; [Through study completion, an average of 11 years, post-mortem analysis after death if applicable]
6. to constitute a biological collection (plasma, DNA, serum). [At the end of the Period of inclusion, around 5-6 years]
